Award notice

Contract summary

Industry

• Research and development services and related consultancy services - 73000000

Location of contract

MK44 2YA

Value of contract

£960,000

Procurement reference

DSTLX-1000161420

Published date

3 August 2021

Closing date

16 July 2021

Closing time

5pm

Contract start date

9 August 2021

Contract end date

8 August 2022

Contract type

Service contract

Procedure type

Call-off from a framework agreement

Contract is suitable for SMEs?

No

Contract is suitable for VCSEs?

No

---

Description

Pathogens of interest for the MoD require timely, specific, lengthy courses of antibiotic therapy. In order to meet the emerging antimicrobial resistance concerns the use of antibiotics must be specific and limited. In addition, potential biological warfare (BW) bacteria are often intracellular and therefore difficult to treat. Delivery of an antibiotic directly into the intracellular environment may increase efficacy. Further, the inclusion of traditional antibiotics with other molecules may reduce prolonged and lengthy antibiotic treatments for intracellular infections. Using smaller amounts of antibiotic in a directed manner should have a lower impact on the host, will limit the amount of antibiotic needed therefore reducing the requirement for lower global use of antibiotic therapies.
Summary of requirement

Under previous Dstl funded contracts, Mologic have been working on developing an antibody-antibiotic conjugate. Dstl require this work to continue in order to help develop this technology further to assist with potentially reducing the length of time for antibiotic treatment.

---

Award information

Awarded date

30 July 2021

Contract start date

9 August 2021

Contract end date

8 August 2022

Total value of contract

£135,000

This contract was awarded to 1 supplier.

MOLOGIC LTD.

---

About the buyer

Address

Porton Down
SALISBURY
SP40JQ
England

Email

cbrcommercial@dstl.gov.uk